Dr. Paul holds a distinguished academic and professional background in clinical laboratory science and biotechnology. He earned his Bachelor of Science in Medical Laboratory Technology from Christian Medical College, Vellore, and later pursued his Master of Science in Biotechnology at Muthayammal College of Arts and Science, Rasipuram. He completed his PhD at VIT, Vellore, where his research significantly contributed to his expertise in biotechnology and healthcare.
Dr. Paul began his career as a Junior Tutor and Medical Lab Technologist at CSI Kalyani Multispeciality Hospital, Chennai, where he developed a strong foundation in clinical laboratory practices and patient diagnostics. While pursuing his master’s degree, he took on the role of Project Trainee at the Tropical Botanic Garden and Research Institute (TBGRI), Palode. During this time, his keen interest in molecular studies began to take shape, leading him to focus more on molecular biology and its applications.
Since August 2007, Dr. Paul has been an integral part of Sri Ramachandra Institute of Higher Education and Research, Chennai. Starting as a Lecturer, he progressed to Senior Lecturer and now serves as an Assistant Professor within the Department of Biotechnology, Faculty of Biomedical Sciences and Technology. His academic and research contributions are centered around the Molecular Biotechnology Lab, where his focus includes microbiome research, SNP genotyping, and the development of phytocompound-based therapies targeting breast cancer.
Through his interdisciplinary approach, combining microbiology, genomics, molecular biology, and bioinformatics, Dr. Paul continues to contribute to advancements in personalized medicine and cancer treatment, making him a key figure in both academic instruction and innovative research.
Our research focuses on screening single nucleotide polymorphisms (SNPs) within the CYP19A1 gene to identify genetic variations associated with breast cancer risk and progression. The CYP19A1 gene encodes the aromatase enzyme, which is crucial for estrogen biosynthesis. Alterations in this gene may influence aromatase activity, potentially driving estrogen-dependent tumor growth in breast cancer patients. By pinpointing specific SNPs linked to breast cancer, our work aims to deepen the understanding of how genetic variations contribute to cancer susceptibility and progression.
To address these challenges in a therapeutic context, we are also computationally screening bioactive compounds from Swietenia macrophylla, a plant known for its medicinal properties. Using advanced molecular docking and simulation techniques, we evaluate these compounds as potential aromatase inhibitors. The goal is to identify compounds that selectively inhibit the aromatase enzyme, thereby reducing estrogen production in a controlled manner to slow down or halt tumor growth in breast cancer.
This research project is at the intersection of genomics and computational drug design, with the ultimate objective of contributing to the development of targeted therapies that can improve outcomes for breast cancer patients. By focusing on natural compound-derived inhibitors, we hope to offer safer, more effective treatment options that minimize side effects and cater to personalized therapeutic needs.
This research investigates the role of Fusobacterium nucleatum, a bacterium commonly found in the oral microbiome, in the development or progression of breast cancer. Recent studies suggest that specific bacteria within the microbiome may contribute to cancer by influencing inflammation, immune response, and other cellular processes associated with tumorigenesis. Given Fusobacterium nucleatum’s known association with various cancers, our work seeks to determine if it may play a similar role in breast cancer.
To achieve this, we are screening and characterizing the virulence factors—molecules produced by F. nucleatum that enhance its ability to colonize, survive, and affect host tissues. By identifying and understanding these virulence factors, we aim to elucidate the potential mechanisms through which F. nucleatum might contribute to cancer risk or tumor progression. This includes investigating how these factors may interact with host cells, influence immune system evasion, and promote pro-carcinogenic environments.
This project is at the forefront of cancer microbiome research, focusing on the intersection of microbiology, oncology, and immunology. By clarifying the role of F. nucleatum in breast cancer, we hope to open new avenues for preventive or therapeutic strategies that target harmful microbiome interactions, potentially leading to novel treatments or risk assessment tools tailored for breast cancer patients.
This project aims to identify and evaluate potential inhibitors of the enzyme 17-beta-hydroxysteroid dehydrogenase (17β-HSD), a key player in estrogen metabolism, for their efficacy in breast cancer treatment. The 17β-HSD enzyme is involved in converting weaker estrogens to their more potent forms, which can drive the growth of estrogen-dependent breast cancer cells. By targeting and inhibiting this enzyme, it is possible to reduce estrogen levels, thereby potentially slowing tumor progression and enhancing therapeutic outcomes for breast cancer patients.
Our research utilizes both in silico (computer-based) and in vitro (laboratory-based) methods to screen, identify, and assess promising 17β-HSD inhibitors. The in silico phase includes molecular docking, virtual screening, and predictive modeling techniques to simulate the binding and efficacy of potential compounds, while the in vitro phase involves rigorous laboratory testing to confirm the effectiveness and safety of these candidates in a controlled environment.
Through this dual approach, we aim to develop and validate novel inhibitors with high specificity and potency against 17β-HSD. This project represents a significant advancement in the search for targeted therapies that can improve breast cancer treatment by limiting estrogen-driven tumor growth, ultimately contributing to the development of safer, more effective treatment options tailored to individual patient needs.
RD Birla Smarak Kosh Fellowship 2005 was awarded for my research while doing my PhD.
Served as the Member in the Board of Studies, Auxilium College, Vellore for Medical Laboratory Technology and Biotechnology courses.